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Abstract 
Background: Secondary peritonitis requires surgical source control and adequate antimicrobial treatment. Anti-
microbial regimens are usually selected according to local susceptibility data of individual pathogens against single 
agents, but this neglects both the polymicrobial nature of the infection and the use of combination therapy. We 
analysed the probability of common regimens to cover all relevant pathogens isolated in one patient (“spectrum 
adequacy rate”, SAR) in a real-life data set.
Methods: Data from 242 patients with secondary peritonitis (88 community acquired, 154 postoperative cases) 
treated in our IMCU/ICU were obtained retrospectively. The relative frequency of pathogens, resistance rates and the 
SAR were analysed using the free software R.
Results: Enterococci were isolated in 47.1 % of all patients, followed by Escherichia coli (42.6 %), other enterobac-
teriaceae (33.1 %), anaerobes (29.8 %) and Candida spp. (28.9 %). Resistance patterns were consistent with general 
surveillance data from our hospital. The susceptibility rates and SAR were lower in postoperative than in community 
acquired cases. The following regimens yielded a SAR > 95 % when enterobacteriaceae only were considered: pipera-
cillin/tazobactam + gentamicin, cefotaxim (only for community acquired cases), cefotaxim + gentamicin, merope-
nem, tigecycline + gentamicin or tigecycline + ciprofloxaxin. When enterococci were also considered, all betalactam 
based regimens required combination with vancomycin or linezolid for a SAR > 95 %, whereas TGC based regimens 
were not compromised. As for Candida spp., the SAR of fluconazole was 81.9–87.5 %.
Conclusions: This study demonstrates a rational approach to assess the adequacy of antimicrobial regimens in sec-
ondary peritonitis, which may help to adjust local guidelines or to select candidate regimens for clinical studies.
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Background
Secondary peritonitis (due to a gastrointestinal perfora-
tion or leakage) is among the leading causes of commu-
nity acquired sepsis. Equally, postoperative secondary 
peritonitis is a dreaded complication of intestinal surgery 
with a high burden of morbidity and mortality. It is easy 
to understand that these are typically polymicrobial 
infections. Second to surgical source control (i.e. closure 
of the perforation and lavage), antimicrobial therapy has 
an important role. Inadequate antimicrobial therapy—
too late, too little, or wrong spectrum—has been shown 
to affect the clinical evolution and outcome [1–3].
This link is less direct than e.g. in pulmonary infections 
where surgery has no role and antimicrobial therapy is 
the only causative therapy. Favourable outcome may also 
be achieved with limited spectrum therapy, directed only 
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against the most common and pathogenic isolates (aero-
bic Gram-negative bacilli and anaerobes). In severe cases, 
however, the presence of drug-resistant organisms and 
also isolates of questionable or facultative pathogenicity 
(such as enterococci and yeasts) should be considered, 
and coverage of all isolated pathogens is preferable.
Ideally, recommendations for empiric treatment 
should be custom tailored to the specific population, so 
that initial treatment will offer an adequate spectrum in 
most and an excessive spectrum in few cases. Whereas 
it is reasonable to consider the relative frequency of iso-
lated species and their individual resistance rates, this 
approach neglects the polymicrobial nature of secondary 
peritonitis. Co-infection by two or more pathogens with 
different resistance patterns will lead to a higher per-
centage of inadequate treatment than individual resist-
ance rates suggest. (For instance, the susceptibility rates 
of Escherichia coli to cephalosporins are notably higher 
than to fluoroquinolones, whereas the opposite is the 
case for many other enterobacteriaceae, e.g. Enterobacter 
spp. or K. pneumoniae [4].) The simultaneous evaluation 
of all pathogens identified in one patient for susceptibil-
ity against an antimicrobial regimen seems a more logical 
approach. To use an analogy to a famous pad-and-pencil 
game: the battleship is only sunk when all parts of it have 
been hit.
With the present study, we provide a retrospective 
analysis of the spectrum adequacy of selected antimicro-
bial regimens in a real-life data set of pathogens cultured 
in patients with secondary peritonitis who were admit-
ted to the surgical intermediate and intensive care unit 
(IMCU/ICU).
Methods
Patient selection and data acquisition
Using our hospital-wide electronic patient file manage-
ment system, we screened every patient who had been 
discharged from (or had deceased in) our IMCU/ICU 
between 1 August 2012 and 31 January 2014 for the 
presence of positive intraabdominal culture results. On 
the basis of the discharge letter and surgical reports, all 
patients who had undergone surgery for a confirmed 
diagnosis of secondary peritonitis were selected, exclud-
ing patients who had not undergone surgery, other forms 
of peritonitis, samples obtained during elective surgery 
without evidence of infection, or misspecified samples 
from other sources. Patients who had been newly admit-
ted for abdominal symptoms, and in whom the intestinal 
perforation was unrelated to previous surgery (e.g. per-
foration of a gastric ulcer or of the sigmoid colon), were 
classified as community-acquired cases (c.a.). When peri-
tonitis was a complication of recent surgery (e.g. anasto-
motic leak), it was classified as postoperative secondary 
peritonitis (p.op.). For each patient, only microbiological 
results from the first laparotomy were included, not from 
subsequent relaparotomies. If a patient had valid swab 
results for community acquired and subsequently for 
postoperative secondary peritonitis, only the first (com-
munity acquired) episode was considered. The anatomi-
cal site of the lesion was registered. Anatomically well 
defined lesions were categorised as stomach/duodenum, 
small intestine or colon. Otherwise, e.g. in cases of mul-
tiple lesions or in intestinal ischemia, it was categorised 
as “other”. In addition to microbiological data, age, sex, 
length of stay in the IMCU/ICU and in the hospital after 
admission on IMCU/ICU, and death was obtained. No 
data on the individual antimicrobial treatment could be 
collected, since these informations are not recorded in 
the electronic patient file management system. For elec-
tive intestinal surgery, the standard for perioperative 
prophylaxis is cefuroxime 1.5 g, in the case of colonic sur-
gery in combination with metronidazole 500 mg, which 
is repeated in cases of prolonged surgery, but is not 
extended beyond the end of the procedure. For laparot-
omy for suspected intestinal perforation, most patients 
in our institution receive either the same regimen as for 
elective surgery (cefuroxime ± metronidazole) or pipera-
cillin/tazobactam 4.5  g preoperatively, and treatment is 
adjusted subsequently according to the intraoperative 
findings and patient specific risk factors.
The responsible ethics committee of the Charité Uni-
versitätsmedizin Berlin gave approval for publication of 
the study results (reference number EA2/045/15).
Microbiological diagnostics
In our hospital, swabs are preferred over other sampling 
techniques (e.g. inoculation of peritoneal fluid into blood 
culture bottles [5]), but results were considered for this 
analysis independent of the used material as long as they 
originated from the peritoneal cavity. Routinely, a swab 
(eSwab™, BD, Heidelberg, Germany) is taken from the 
interenteric fluid immediately after opening of the peri-
toneal cavity; further samples may be obtained from 
suspect sites at the discretion of the surgeon. Samples 
are transferred to the central microbiological labora-
tory (Labor Berlin GmbH) and processed using standard 
techniques: swabs were applied onto routine microbio-
logical media (Columbia blood, chocolate, McConkey, 
Schaedler, Sabouraud agar plates and thioglycolate 
broth), incubated at 36  °C with or without CO2, under 
aerobic or anaerobic conditions, respectively. Aerobic 
media were read on day 1 and 2, anaerobic media on day 
2. Aerobic bacteria were identified by biochemical meth-
ods (Vitek2, bioMérieux, France) or by mass spectrom-
etry (microflex with Biotyper software, Bruker Daltonics, 
Germany, or VitekMS, bioMérieux, France). Vitek2 was 
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used for antimicrobial testing. For selected microorgan-
isms we used standard agar diffusion procedures (Kirby 
and Bauer) or E-Test (bioMérieux, France) to establish 
antibiograms [6, 7]. Interpretation of breakpoints was 
done using EUCAST clinical breakpoint tables (http://
www.eucast.org/clinical_breakpoints/). Divergent from 
the EUCAST expert rules in antimicrobil susceptibility 
testing [8], the susceptibility of ESBL producing entero-
bacteriaceae against betalactam/betalactamase inhibi-
tor combinations (SAM, TZP) and cephalosporins was 
reported as resistant (instead of as tested with a warning 
on uncertain therapeutic outcome).
Data analysis
The statistical package ‘R’ (V3.1.1 for MacOSX, R foun-
dation for statistical computing, Vienna, Austria) with 
‘RStudio’ (RStudio Inc., Boston, MA, USA) was used for 
the analysis, Prism (V6.0d for MacOSX, GraphPad Soft-
ware, La Jolla, CA, USA) for graphical presentation of the 
results.
The following tasks were performed by an R-script:
1. Elimination of copy strains.
2. Classification of isolates into the following categories: 
E. coli, enterobacteriaceae other than E. coli, non-
fermenting Gram-negative rods, enterococci, strep-
tococci, S. aureus, coagulase-negative staphylococci, 
anaerobes, Candida spp., and others.
3. Tabulation of resistance/susceptibility for each of 
these categories.
4. Tabulation of the prevalence of the pathogen catego-
ries sorted by diagnosis and anatomical location of 
the lesion.
5. Calculation of the spectrum adequacy rate (SAR) 
for selected antimicrobial regimens. The spectrum 
was adequate if all isolated enterobacteriaceae or 
all enterobacteriaceae plus enterococci in the same 
patient were susceptible to the tested regimen; can-
dida spp. were tested separately. The SAR is reported 
as percentage of the patients within the same setting 
(community acquired or postoperative).
The results of 3 and 4 were used to describe and com-
pare the results with local susceptibility data or other 
studies. Task 5 was the primary purpose of this study.
Results
The relevant population was composed of 242 patients 
who had undergone surgery for confirmed secondary 
peritonitis, among which 88 had community acquired 
and 154 postoperative peritonitis. Case characteristics 
are displayed in Table  1. A total of 654 different strains 
was isolated, details are shown in Table  2. The number 
of isolated pathogens per patient was equal in commu-
nity acquired and postoperative disease (median 2, inter-
quartile range 1–4), the maximum number observed 
being eight. Figure 1 gives a graphical representation of 
the simultaneous isolation of relevant pathogens. Over-
all, Enterococcus spp. was the most prevalent category of 
pathogens, and was isolated in a high percentage of cases 
independently of the clinical setting or the anatomical 
site of intestinal lesion (Fig. 2). Escherichia coli was also 
isolated in about 40 % of the cases independently of the 
clinical setting, but was far less common in proximal than 
in distal intestinal lesions. The opposite was true for Can-
dida spp., being cultured in about 70 % of gastroduode-
nal lesions, but in less than 20 % of those in the colon or 
rectum.
The rates of susceptibility and resistance for the most 
relevant categories of pathogens are shown in Table  3. 
Generally, susceptibility rates were lower in postoperative 
cases. The same trend was observed for SAR (Table  4). 
Against enterobacteriaceae, CTX was superior to TZP 
when used alone (c.a./p.op. 95.5/83.8 vs. 86.4/69.5  %). 
Combinations of these two with GEN enhanced the 
respective SAR to 96.8–98.9 %. As for TGC, the SAR for 
Table 1 Case characteristics
a median (range)
b median (interquartile range)




n (m/f ) 88 (44/44) 154 (94/60) 242 (138/104)
Agea 70 (14–98) 65 (18–89) 66.5 (14–98)
Died in hospital (%) 17 (19.3 %) 28 (18.2 %) 45 (18.6 %)
LoS ICUb 2.5 (1–7.25) 9 (3–21) 5 (2–17)
LoS hospitalb 12 (8–19.25) 23.5 (14–42) 18 (10–34)
Site of lesion
 Stomach/duodenum 13 (14.8 %) 10 (6.5 %) 23 (9.5 %)
 Small intestine 15 (17.0 %) 33 (21.4 %) 48 (19.8 %)
 Colon/rectum 37 (42.0 %) 47 (30.5 %) 84 (34.7 %)
 Other or multiple 23 (26.1 %) 64 (41.6 %) 87 (36.0 %)
Isolated pathogens
 E. coli 40 (45.5 %) 63 (40.9 %) 103 (42.6 %)
 Non-E. coli entero-
bacteriaceae
26 (29.5 %) 54 (35.1 %) 80 (33.1 %)
 Enterococcus spp. 30 (34.1 %) 84 (54.5 %) 114 (47.1 %)
 Streptococcus spp. 26 (29.5 %) 24 (15.6 %) 50 (20.7 %)
 Anaerobes 32 (36.4 %) 40 (26.0 %) 72 (29.8 %)
 Candida spp. 26 (29.5 %) 44 (28.6 %) 70 (28.9 %)
 Non-fermenter 7 (8.0 %) 8 (5.2 %) 15 (6.2 %)
 S. aureus 4 (4.5 %) 9c (5.8 %) 13 (5.4 %)
 CoNS 5 (5.7 %) 15 (9.7 %) 20 (8.3 %)
 Others 8 (9.1 %) 11 (7.1 %) 19 (7.9 %)
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monotherapy was only ~84 % against enterobacteriaceae 
due to the frequent isolation of resistant Proteus spp., 
along with some isolates of K. pneumoniae or E. cloacae 
with intermediate susceptibility or resistance. This could 
be amended by combination of TGC with CTX, CIP or 
GEN (SAR 92.2–99.4  %). Monotherapy of CIP would 
have been active in 87.7–93.2 % of patients, and MEM in 
100 %.
When enterobacteriaceae and enterococci were evalu-
ated together, the SAR of CTX-based regimens without 
anti-enterococcal activity dropped to 41.6–65.9  %. Due 
to the high occurrence of ampicillin-resistance in ente-
rococci (~1/3), the SAR of TZP also decreased (58.1–
84.1 %). Due to a percentage of 5.6–11.3 % of resistance 
to VAN among all isolated enterococci (mainly in E. fae-
cium), these effects were only partially reversed by addi-
tion of VAN, but almost fully by addition of LZD. Since 
resistance to TGC was not observed among enterococci, 
SARs of its combinations were identical to those against 
enterobacteriaceae only. Assuming anti-enterococcal 
activity of MEM (the MICs of MEM for enterococci are 
typically two- to  fourfold higher than for ampicillin or 
imipenem), the hit-rate of MEM was determined by the 
presence of ampicillin-resistant enterococci, and was 
78.6–87.5 % when used as single agent, 94.2–98.9 % when 
combined with VAN and 98.9–99.4  % when combined 
with LZD.
Since antibacterial and antifungal agents do not share 
any common spectrum, the SAR of FLC was evaluated 
separately, and was 81.9–87.5  %. Of note, FLC-resist-
ant strains were isolated only in 1.1–2.6  % of patients, 
whereas there was a considerable number of strains 
with intermediate (n  =  16) or undetermined (n  =  19) 
susceptibility.
Discussion
With the present study, we provide an evaluation of 
antimicrobial agents, used alone or in combination, in a 
Table 2 Pathogens cultured from intraabdominal swabs in 242 patients with secondary peritonitis
Escherichia coli (107) Anaerobes (100)
 Actinomyces turicensis (1)
 Bacteroides caccae (2)
 Bacteroides capillosus (1)
 Bacteroides eggerthii (1)
 Bacteroides fragilis (33)
 Bacteroides intestinalis (1)
 Bacteroides ovatus (8)
 Bacteroides sp. (2)
 Bacteroides stercoris (1)
 Bacteroides thetaiotaomicron (7)
 Bacteroides uniformis (2)
 Bacteroides vulgatus (13)
 Clostridium fallax (1)
 Clostridium perfringens (1)
 Clostridium septicum (1)
 Clostridium sordellii (1)
 Clostridium sp. (1)
 Clostridium symbiosum (1)
 Clostridium tertium (2)
 Fusobacterium necrophorum (1)
 Fusobacterium nucleatum (2)
 Fusobacterium sp. (1)
 Fusobacterium varium (1)
 Lactococcus garvieae (1)
 Leuconostoc sp. (1)
 Parabacteroides distasonis (8)
 Parabacteroides johnsonii (1)
 Pediococcus acidilactici (1)
 Peptostreptococcus anaerobius (1)
 Prevotella denticola (2)
Streptococcus spp. (61)
 S. agalactiae (1)
 S. anginosus (19)
 S. constellatus (6)
 S. cristatus (1)
 S. dysgalactiae (4)
 S. gordonii (1)
 S. infantarius (2)
 S. intermedius (2)
 S. massiliensis (1)
 S. mitis/oralis (11)
 S. parasanguinis (3)
 S. peroris (1)
 S. salivarius (3)
 S. sanguinis (4)
 S. vestibularis (1)
 Streptococcus sp. (1)
Non-E. coli Enterobacteriaceae (105)
 Citrobacter braakii (3)
 Citrobacter freundii (9)
 Enterobacter aerogenes (1)
 Enterobacter cloacae (21)
 Hafnia alvei (3)
 Klebsiella oxytoca (13)
 Klebsiella pneumoniae (26)
 Morganella morganii (2)
 Proteus mirabilis (13)
 Proteus penneri (5)
 Proteus vulgaris (9)
Candida spp. (77)
 C. albicans (33)
 C. krusei (1)
 C. dubliensis (1)
 C. glabrata (24)
 C. krusei (1)
 C. lusitaniae (1)
 C. norvegensis (1)
 Candida sp. (13)
 C. tropicalis (2)
Others (21)
 Aerococcus viridans (1)
 Aeromonas veronii (1)
 Bacillus cereus (1)
 Bacillus licheniformis (1)
 Bifidobacterium sp. (1)
 Corynebacterium sp. (1)
 Corynebacterium striatum (1)
 Gemella morbillorum (2)
 Geotrichum sp. (1)
 Lactobacillus brevis (1)
 Lactobacillus fermentum (1)
 Lactobacillus gasseri (1)
 Lactobacillus paracasei (1)
 Lactobacillus paraplantarum (1)
 Lactobacillus rhamnosus (1)
 Lactobacillus salivarius (1)
 Lactobacillus sp. (2)
 Rothia mucilaginosa (1)





 E. avium (11)
 E. casseliflavus (1)
 E. dispar (1)
 E. faecalis (61)
 E. faecium (56)
 E. gallinarum (3)
 E. hirae (1)
Non-fermenter (15)
 Acinetobacter baumannii (2)
 Pseudomonas aeruginosa (12)
 Stenotrophomonas maltophilia (1)
CoNS (21)
 S. capitis (2)
 S. epidermidis (14)
 S. haemolyticus (5)
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real-life data set of culture results from patients with sec-
ondary peritonitis who required intermediate or inten-
sive care. It is important to stress the virtual character of 
this analysis; a regimen was considered adequate when all 
relevant pathogens isolated in one patient were suscepti-
ble to at least one of its components. No information on 
the clinical efficacy of the actual treatment was obtained 
or analysed. The advantage of this approach is that many 
potential regimens can be tested within a specific clinical 
and epidemiological context, and the results can be used 
e.g. to adjust local or regional treatment guidelines, or 
select promising candidate regimens for clinical trials. In 
contrast to ordinary surveillance data which report activ-
ity of single agents against single species (or genera), this 
approach also allows to evaluate the effect of the combi-
nation of more than one agent and more than one patho-
gen, as is usually the case in secondary peritonitis.
Representativeness of pathogen data is crucial. 
Although data quality (with regard to patient charac-
teristics and diagnostic procedures) may be highest in 
clinical trials e.g. of new antimicrobial agents, such stud-
ies are likely to represent a highly selected population of 
tendentially less severe cases (particularly appendicitis) 
in younger and healthier patients than encountered in 
clinical practice [9, 10]. For the present study, the most 
important criterion for inclusion was admission to the 
surgical IMCU/ICU. Patients with clearly mild disease 
and good general health were therefore not included into 
this analysis, as evidenced by the high mortality of 18.5 %. 
The distribution of pathogens was generally similar to 
that reported by other studies [11–13]. Susceptibility 
rates were in fair agreement with the general surveil-
lance data from our hospital. Carbapenemase-producing 
enterobacteriaceae (CRE) are still not endemic and were 
not observed in this study, whereas about 10 % of E. coli 
express ESBL, and about 25 % are resistant to fluoroqui-
nolones. Resistance rate to vancomycin is found in about 
20 % of E. faecium. For almost all agents, resistance rates 
were higher in postoperative than in community acquired 
cases, as has been described previously [13].
Anaerobes, streptococci, staphylococci and non-fer-
menters were excluded from the spectrum adequacy eval-
uation. There is consensus that activity against anaerobes 
should be provided in most cases [5, 14], and agents lack-
ing such activity (e.g. CTX, CIP) are typically combined 
with metronidazole to close this gap. No drug-resistance 
at all was detected in streptococci, and their inclusion 
would therefore not change the results of the analysis. 
Coagulase-negative staphylococci are mostly resistant to 
betalactam antibiotics (18 out of 21 isolates in this study), 
but are considered rather contaminants than pathogens 
without the context of peritoneal dialysis. Some strains of 
Staphylococcus aureus and non-fermenters were isolated, 
both in community acquired (4 S. aureus, 6 P. aeruginosa, 
1 A. baumannii) and postoperative cases (9 S. aureus, 6 
P. aeruginosa, 1 A. baumannii, 1 S. maltophilia). Two iso-
lates of P. aeruginosa isolated in postoperative cases were 
resistant to TZP and either ceftazidime or MEM, respec-
tively, but fully susceptible to CIP and GEN. All other 
E. coli (n=40) 
Enterococcus spp. (n=30) 
Non-E. coli
Enterobacteriaceae (n=26) 
Candida spp. (n=26) 
Patient number
a
20 40 60 8088
40 80 120 154
E. coli (n=63) 
Enterococcus spp. (n=84) 
Non-E. coli
Enterobacteriaceae (n=54) 
Candida spp. (n=44) 
Patient number
b
Fig. 1 Concomitant isolation of selected pathogens in single 
































Fig. 2 Prevalence of selected groups of pathogens isolated in 
patients with secondary peritonitis, according to site of lesion
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non-fermenters showed “wild type” susceptibility to all 
eligible agents. Only three isolates (all in postoperative 
cases) of Staphylococcus aureus were methicillin-resistant. 
Due to the low numbers of MRSA and non-fermenters, 
their impact on the present analysis was expected to be 
insignificant and of little reliability. This would probably 
be different if follow-up swabs of repeated laparotomies 
in cases with unfavourable evolution were considered, in 
which fastidious pathogens with multi-drug resistance 
may even dominate, and possibly be responsible for the 
insufficient response to therapy.
The main finding of this analysis is that even in an envi-
ronment with moderate resistance rates among entero-
bacteriaceae, popular antimicrobial regimens such as 
Table 3 Rates of susceptibility and resistance in important categories of pathogens isolated in patients with secondary 
peritonitis
missing to 100 % intermediate susceptibility
n number of tested isolates,  %S susceptible,  %R resistant
a Susceptibility of Enterococcus spp. against TZP and MEM was assumed to be identical to that against SAM, which was inferred from that against ampicillin
E. coli Non-E. coli enterobacteriaceae Enterococcus spp. Candida spp.
n %S %R n %S %R n %S %R n %S %R
SAM
 c.a. 41 63.4 36.6 36 61.1 38.9 36 66.7 30.6
 p.op. 66 48.5 51.5 68 44.1 55.9 98 65.3 35.7
TZP
 c.a. 41 78.0 9.8 36 91.7 2.8 a
 p.op. 66 60.6 19.7 68 61.8 23.5
CXM
 c.a. 41 87.8 12.2 36 66.7 33.3
 p.op. 66 75.8 24.2 67 55.2 44.8
CTX
 c.a. 41 95.1 0 36 94.4 5.6
 p.op. 66 84.8 6.1 69 72.5 23.2
ETP
 c.a. 41 100 0 36 97.2 2.8
 p.op. 66 100 0 66 92.4 7.6
MEM
 c.a. 41 100 0 36 100 0 a
 p.op. 66 100 0 69 100 0
CIP
 c.a. 41 82.9 14.6 36 97.2 2.8
 p.op. 66 72.7 22.7 69 97.1 1.4
GEN
 c.a. 41 97.6 2.4 36 97.2 2.8
 p.op. 66 92.4 7.6 69 97.1 2.9
TGC
 c.a. 41 95.1 2.4 36 58.3 33.3 36 100 0
 p.op. 66 100 0 69 55.1 30.4 98 100 0
VAN
 c.a. 36 94.4 5.6
 p.op. 97 88.7 11.3
LZD
 c.a. 36 97.2 2.8
 p.op. 98 99.0 1.0 
FLC
 c.a. 21 76.2 4.8
 p.op. 37 56.8 10.8
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Table 4 Spectrum adequacy of  selected antimicrobial regimens in  patients presenting with  secondary peritonitis (88 
community acquired cases, c.a.; 154 postoperative cases, p.op.)
TZP TZP + GEN TZP + VAN TZP + LZD
c.a. p.op. c.a. p.op. c.a. p.op. c.a. p.op.
Enterobacteriaceae
 %S 86.4 69.5 97.7 96.8
 %R 5.7 18.2 0 0
Enterobacteriaceae plus enterococci
 %S 72.7 58.4 84.1 75.3 85.2 67.5 85.2 69.5
 %R 18.2 33.8 12.5 21.4 6.8 22.1 6.8 18.2
CTX CTX + GEN CTX + VAN CTX + LZD
c.a. p.op. c.a. p.op. c.a. p.op. c.a. p.op.
Enterobacteriaceae
 %S 95.5 83.8 98.9 97.4
 %R 2.3 11.7 1.1 1.3
Enterobacteriaceae plus enterococci
 %S 62.5 41.6 65.9 43.5 93.2 77.9 94.3 83.1
 %R 35.2 57.1 34.1 55.2 4.5 16.9 3.4 12.3
MEM MEM + VAN MEM + LZD
c.a. p.op. c.a. p.op. c.a. p.op. c.a. p.op.
Enterobacteriaceae
 %S 100 100
 %R 0 0
Enterobacteriaceae plus enterococci
 %S 87.5 78.6 98.9 94.2 98.9 99.4
 %R 12.5 20.8 1.1 5.8 1.1 0.6
CIP CIP + VAN CIP + LZD
c.a. p.op. c.a. p.op. c.a. p.op. c.a. p.op.
Enterobacteriaceae
 %S 93.2 87.7
 %R 5.7 9.7
Enterobacteriaceae plus enterococci
 %S 63.6 39.6 90.9 80.5 92.0 87.0
 %R 12.5 37.0 5.7 13.0 5.7 10.4
TGC TGC + GEN TGC + CIP TGC + CTX
c.a. p.op. c.a. p.op. c.a. p.op. c.a. p.op.
Enterobacteriaceae
 %S 84.1 83.1 97.7 99.4 98.9 98.7 98.9 92.2
 %R 11.4 13.0 1.1 0.6 0 0.6 0 1.9
Enterobacteriaceae plus enterococci
 %S 84.1 83.1 97.7 99.4 98.9 98.7 98.9 92.2
 %R 11.4 13.0 1.1 0.6 0 0.6 0 1.9
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TZP or CTX (plus metronidazole) provided only lim-
ited coverage (69.5–95.5 %) when all enterobacteriaceae 
found in one patient were considered. Combination of 
these agents with an aminoglycoside—as suggested by 
the IDSA guidelines [5] when resistant organisms are 
suspected—could considerably improve the spectrum 
adequacy rate. No carbapenem-resistant enterobacte-
riaceae were observed in this study, leaving carbapenems 
such as MEM as a theoretically fail-safe option.
When enteroccoci are of concern, the intrinsically 
active betalactams (TZP, MEM) alone did not provide 
reliable coverage due to a high percentage of ampicillin-
resistant strains. This calls for combination with linezolid 
or vancomycin. Particularly with regard to enterococci, 
TGC offers an interesting spectrum, with no resistance 
observed in this study. Additionally, TGC has activity 
in multi-drug resistant enterobacteriaceae, including 
CRE, and it is approved as monotherapy for treatment 
of complicated intra-abdominal infection. However, the 
SAR of TGC monotherapy remained below 85  %. It is 
interesting that these rates were nearly identical in com-
munity acquired and postoperative cases, maybe indicat-
ing that the mechanisms leading to increasing resistance 
to other agents do not (yet) apply in the same way to 
TGC. In fact, reasons for inadequacy were mostly isola-
tion of Proteus spp., which is generally easy to treat, but 
not a suitable target for TGC. Addition of CIP or GEN 
(or less effectively CTX) could close this gap. However, 
tigecycline has been associated with increased mortal-
ity and noncure-rates [15], and should be reserved for 
situations when alternative treatments are not suitable 
[16]. The rather low plasma concentrations compared 
to sensitivity breakpoints and the bacteriostatic activity 
of tigecycline have been discussed as potential explana-
tions for the higher rate of treatment failure [15], but 
the defined limitations in spectrum (Proteus spp., P. aer-
uginosa) might also contribute. Although this is purely 
speculative, there may be more than one good reason 
for combination of tigecycline with a “classical” bacteri-
cidal agent such as a betalactam, a fluoroquinolone or an 
aminoglycoside.
Bearing the limitations of our analysis in mind, these 
results may offer some guidance on what antibacterial 
regimen to choose in cases of the highest severity and 
risk. Considering the regimens with a SAR of 95–100 %, 
these would be triple combinations of TZP or CTX (each 
plus GEN plus VAN or LZD), or double combinations 
with MEM (plus VAN or LZD) or TGC (plus CIP or 
GEN) for community acquired or postoperative perito-
nitis. For cases of lower severity and risk, regimens with 
lower SAR can be selected. Since the SAR is a patient-
based index, differences can be directly translated into 
a number needed to treat. Irrespective of the absolute 
value, a regimen with a 5 % lower SAR will leave 1 addi-
tional patient out of 20 with formally inadequate spec-
trum, which may or may not affect clinical outcome. This 
consideration may be particularly helpful when the alter-
native with higher SAR is either costly (e.g. LZD, TGC) 
or toxic (e.g. GEN, VAN).
Some limitations of our analysis must be discussed. 
First, because all data were obtained retrospectively, sev-
eral relevant aspects of the case characteristics were no 
longer accessible to us, particularly those on the indi-
vidual antimicrobial treatment. All samples were prob-
ably obtained after some antibiotic (at least perioperative 
prophylaxis for laparotomy) had been administered. It 
is therefore possible that some susceptible pathogens 
may have been lost to detection. This would be prob-
lematic if ultra-broad spectrum antibiotics or combina-
tions had often been used (eradicating even pathogens of 
“typical” resistance), or if a large number of samples had 
appeared to be completely sterile (excluding these cases 
completely from the analysis). Then, the prevalence of the 
more persistent and/or resistant pathogens could have 
been grossly overestimated. However, the microbiologi-
cal patterns we observed are fairly consistent with results 
from other studies and our local surveillance data. Severe 
underrepresentation of highly susceptible pathogens (e.g. 
streptococci) would be of academic, but not of thera-
peutic importance. Second, antimicrobial susceptibility 
testing may be inaccurate. In particular, variable results 
have been reported for TZP with automated systems [17, 
%S: all pathogens of the respective categories are susceptible to the tested antimicrobial regimen, or no pathogen of the respective categories was isolated.  %R: at 
least one pathogen of the respective categories is resistant to all agents of the tested regimen. Missing to 100 %: no full, but intermediate or unknown susceptibility of 
at least one pathogen to at least one agent
Table 4 continued
FLC
c.a. p.op. c.a. p.op. c.a. p.op. c.a. p.op.
Candida spp.
 %S 87.5 81.9
 %R 1.1 2.6
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18]. The epidemiological cut-off values (ECOFF) of most 
enterobacteriaceae for TZP is identical (8  mg/L) to the 
susceptibility breakpoint (EUCAST rationale documents: 
http://www.eucast.org/documents/rd), and small varia-
tions of the test result may easily lead to categorisation 
of susceptible strains as intermediate. For cefotaxime, 
in contrast, the categorisation is probably more robust 
because the ECOFF is typically one or several log2-steps 
lower than the breakpoint. However, it is unlikely that 
erroneous categorisation of some isolates would have rel-
evant effects on the global trends of our analysis. Third, 
our assessment of spectrum-adequacy was done irre-
spective of relative pathogenic relevance of the isolates, 
which is unlikely to represent the biological reality of 
secondary peritonitis. However, to our knowledge, these 
aspects are not sufficiently understood to be included 
into a model with clinical data; given the rather loose 
association between antimicrobial therapy and thera-
peutic success, there is certainly still much to be learned 
about the pathogen-host interaction in secondary perito-
nitis. All in all, although more detailed and refined anal-
ysis are certainly possible, we consider our results to be 
valid and clinically relevant.
Conclusions
We developed a simple but innovative quantitative 
method to assess the spectrum adequacy of antimicrobial 
regimens to be used for polymicrobial infections (“bat-
tleship approach”), and applied it to a real-life data set of 
pathogens cultured in patients with secondary peritonitis 
admitted to the IMCU/ICU. The results of this approach 
can be used as a rational base to inform e.g. the local 
adaption of guidelines.
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